|
|
|
|
|
|
| (especial para SIIC © Derechos reservados) |
| Ramón Salazar* Autor invitado por SIIC |
|
 Profundizar Referencias bibliográficas |
| Eriksson B, Klöppel G, Krenning E, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors: well differentiated jejunal–ileal tumor/carcinoma. Neuroendocrinology 2008; 87:8–19. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC and Meric-Bernstam F. Antitumor activity of rapamycin and octeotride as single agents or in combination in neuroendocrine tumours. Endocrine-Related Cancer, 2008; 15:257-266. Rinke A, Müller H, Schade-Brittinger C, Klose K, Barth P, et al. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group. JCO 2009; 27 (28):4656-4663. Stephan Wullschleger, Robbie Loewith and Michael N. Hall. TOR Signaling in Growth and Metabolism. Cell 2006; 124:471-484. [doi 10.1016/j.cell.2006.01.016]. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5 (8): 671-88. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. JCO 2009; 27 (13): 2278-87. Salazar R., Reidy-Lagunes D., and Yao J. Potential Synergies for Combined Targeted Therapy in the Treatment of Neuroendocrine Cancer. Drugs, 2011; 71(7):841-852. Albanell J, Dalmases A, Rovira A and Rojo F. mTOR signaling in human cancer. Clinical Translational Oncology 2007; 9:484-93. Shida T, Kishimoto T, Furuya M, et al. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother Pharmacol 2010; 65: 889-93. James C. Yao, M.D., Manisha H. Shah et al. Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N Engl J Med 2011; 364:514-23. Pavel M, Hainsworth JD, Baudin E et al. A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus + octreotide LAR versus placebo + octreotide LAR in patients with advanced neuroendocrine tumors (RADIANT-2). Ann Oncol 2010, 21 (suppl 8): viii4 (LB A8) [doi:10.1093/annonc/mdq601]. James C. Yao, Catherine Lombard-Bohas, Eric Baudin, et al. Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial. JCO 2010; 29(1):69-76. von Wichert G, Jehle PM, Hoeflich A, et al. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res, 2000; 60:4573-4581. |
| Otros artículos de Ramón Salazar |
| Salazar R, Wiedenmann B, Rindi G, Ruzsinewski P. ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update. Neuroendocrinology, 2011 Dec 23. [Epub ahead of print] Salazar R., Reidy-Lagunes D., and Yao J. Potential Synergies for Combined Targeted Therapy in the Treatment of Neuroendocrine Cancer. Drugs, 2011; 71(7):841-852. Capdevila J, Salazar R, Halperín I, Abad A, Yao JC. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors. Cancer Metastasis Rev., 2011; 30 Suppl 1:27-34. Review. Babel I, Barderas R, Diaz-Uriarte R, Moreno V, Suarez A, Fernandez-Aceñero MJ, Salazar R, Capellá G, Casal JI. Identification of MST1/STK4 and SULF1 proteins as autoantibody targets for the diagnosis of colorectal cancer by using phage microarrays. Mol Cell Proteomics., 2011; 10(3):M110.001784. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, Bruin S, Kerr D, Kuppen P, van de Velde C, Morreau H, Van Velthuysen L, Glas AM, Van't Veer LJ, Tollenaar R. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol., 2011; 29(1):17-24. Eriksson B, Annibale B, Bajetta E, Mitry E, Pavel M, Platania M, Salazar R, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology., 2009; 90(2):214-9. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol., 2008; 9(1):61-72. Review. Vilar E, Salazar R, Perez-García J, Cortes J, Öberg K, and Tabernero J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocrine-Related Cancer, 2007; 14:221–232. Durán I, Salazar R, Casanovas O, Arrazubi V, Vilar E, Siu L L, Yao J and Tabernero J. New drug development in digestive neuroendocrine tumors. Annals of Oncology, 2007; 18: 1307–1313. Salazar R, Villabona C, Fabregat J. Gastrointestinal and pancreatic neuroendocrine tumors. Med Clin (Barc), 2006; 127(6):227-31. Review. |
|
Acerca del trabajo completo |
| NUEVAS OPCIONES DE TRATAMIENTO COMBINADO INHIBIDOR DE LA VIA DE MTOR EN TUMORES NEUROENDOCRINOS |
| Título original en castellano POSIBLES SINERGIAS PARA LA TERAPIA DIRIGIDA COMBINADA EN EL TRATAMIENTO DE CANCER NEUROENDOCRINO |
| Autor Ramón Salazar1 |
| 1 Doctor en Medicina, Institut Català D'oncologia, Head. Early Clinical Research Unit; Head |
| Acceso a la fuente original Drugs |
| http://adisonline.com/drugs/Pages/default.aspx |
Acceso al texto original completo (full text) |
Acceso al resumen/abstract original |
| El artículo se relaciona estrictamente con las especialidades de siicsalud | |
|
ua90911 |
Acerca de SIIC Estructura de SIIC
|
|
Sociedad Iberoamericana de Información Científica (SIIC)
Av. Belgrano 430, (C1092AAR), Buenos Aires, Argentina Tel: +54 11 4342 4901; Fax: +54 11 4331 3305 Casilla de Correo 2568, (C1000WAZ) Correo Central, Buenos Aires Copyright siicsalud© 1997-2013, Sociedad Iberoamericana de Información Científica (SIIC) ISSN siicsalud: 1667-9008 ua4711 Mensajes a SIIC |
